Celmatix Announces the Reproductive AtlasTM Project, Aimed at Building the Richest Knowledgebase of Reproductive Potential in the World

Project to bring together academic research centers, physicians,
and leaders in biotech to advance population-scale understanding of the
intersection of data related to fertility

NEW YORK–(BUSINESS WIRE)–Celmatix, a next-generation women’s health company, today announced the
Reproductive Atlas project, which is aimed at building an unprecedented
knowledgebase about human reproductive potential. This database will
incorporate biological annotations refined from the peer-reviewed
literature with genomic data linked to data about lifestyle, diet,
environment, and reproductive outcomes. The project aims to build the
first population-scale dataset built for understanding reproductive
health, incorporating a diverse cross-section of ethnic, geographic, and
socioeconomic groups.

“Celmatix has been amassing genetic, biological, and clinical data
related to fertility for almost a decade, however, most of it has been
focused on individuals already affected by reproductive conditions and
difficulties. Building the Reproductive Atlas knowledgebase will help us
take this data to the next level. We want to ensure that over time, we
can deliver the best products possible to a diverse group of women,
earlier in their lives before reproductive conditions begin,” stated
Celmatix Founder and CEO, Dr. Piraye Yurttas Beim, PhD. She continued,
“Many other industries, including oncology, have been able to rely on
insights generated by academia. However, the field of women’s
reproductive health and fertility is one of the lowest funded of all
areas of medicine. This project was created to fill that gap by
providing a better understanding of the impact of genomics, diet,
lifestyle, and environment on all women’s fertility, regardless of known
risk factors. We know that genomic data has predictive power, but is
rarely destiny on its own. By collaborating with the top scientists,
physicians, companies, and institutions who share this passion for
progressing reproductive health, we will be able to create a rich
knowledgebase for our field to better understand how these genetic and
non-genetic factors intersect to impact reproductive health.”

Celmatix will collaborate with a number of research centers and biotech
leaders on this initiative. The first new study to launch through the
Reproductive Atlas project is with the BioMe™ BioBank Program of
the Charles Bronfman Institute for Personalized Medicine at the Icahn
School of Medicine at Mount Sinai in New York City.

“We are thrilled to be participating in this study with Celmatix and to
be a collaborator in the Reproductive Atlas project,” stated Amanda
Merkelson, MPH, Managing Director of BioMe. “One of the missions
of BioMe is to accelerate initiatives like this through linking
data that has been shared by patients in the Mount Sinai Health System
who are passionate about progressing personalized medicine and genomics.
This project, by focusing specifically on a condition as delicate and as
pervasive as infertility and potentially impacting all women’s
reproductive health, allows Mount Sinai to help further this mission.”

Celmatix will be announcing additional collaborators as part of the
Reproductive Atlas project in the coming months.

About Celmatix

Celmatix is a next-generation women’s health company transforming
reproductive health care through genomics and big data. Founded in 2009
and based in New York City, Celmatix is disrupting how women approach
their lifelong fertility journey by empowering them with more
personalized information. The company’s research-driven products include
Fertilome, the world’s first comprehensive genetic screen that reveals
what a woman’s DNA says about her reproductive health, and Polaris, a
real-time predictive analytics platform in use at leading fertility
clinics across the U.S., which helps physicians optimize patient
outcomes and improve the patient experience. For more information, visit www.celmatix.com.

Contacts

for Celmatix
Rachel Petersen, 262-206-0627
rachel@brewpr.com